Incretin strategy in the treatment of type 2 diabetes mellitus - DPPIV;Inkretinová strategie léčby diabetes mellitus 2. typu - DPP-IV

Vnitrni Lekarstvi

Volumn 53, Issue 9, 2007, Pages 1005-1009

  Perušičová, Jindřiška ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

DPPIV; GLP 1; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; INCRETIN; METFORMIN;

GLUCOSE HOMEOSTASIS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN DEGRADATION; REVIEW; RISK REDUCTION;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN;

EID: 34948813494     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Ahrén B. What mediate the benefits associated with dipeptidyl peptidase-IV inhibition? Diabetologia 2005; 48: 605-607.
2. Ahrén B. Inhibition of dipeptidyl peptidase-IV reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocr Metab 2004; 89: 2078-2084.
3. Ahrén B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003; 3: 365-372.
4. Ahrén B. Glucagon-like peptide 1 (GLP-1) - a gut hormone of potential interest in the treatment of diabetes. Bioesays 1998; 20: 642-651.
5. Bray GM. Exenatide. Am J Health Syst Pharm 2006; 63: 411-418.
6. Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42: 222-229.
7. Burcelin R, Dolci W, Thorens B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagons-like peptide-1. Metabolism 1999; 48: 252-258.
8. Buse JB, Henry RR, Han J et al. for the Exenatide-113 Clinical Study Group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulphonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
9. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985; 28: 565-573.
10. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142: 521-527.
11. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Invest Drugs 2003; 12: 87-100.
12. Gautier JF, Fetita S, Sobngwi E et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005; 31: 233-242.
13. Green BD, Irwin N, Flatt PR. Pituitary adenylate cyclase-activating peptide (PA-CAP): Assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential. Peptides 2006; 27: 1349-1358.
14. Holst JJ, Deacon FC. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005; 48: 612-615.
15. Hui H, Zhao X, Perfetti R. Structure and function studies of glucagon-like peptide 1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab Res Rev 2005; 21: 313-331.
16. Hui H, Farila L, Merkel P et al. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 2002; 146: 863-869.
17. Hu H, Norparvar A, Yhao X et al. Glucagon-like peptide-1 inhibits apoptosis of insulin secreting cells via a cyclic 5′adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003; 144: 1444-1455.
18. Hupe-Sodmann K, McGregor GP, Bridenbaugh R et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36) amide and comparison of the substrate specificity of the enzyme for other glucagons-like peptides. Regul Pept 1995; 58: 149-156.
19. Gedulin BR, Nikoulina SE, Smith PA et al. Exenatide (exendin 4) improves insulin sensitivity and b-cell mass in insulin resistant obese fa/fa Ucker rats independent of glycemia and body weight. Endocrinology 2005; 146: 2069-2076.
20. Iltz JL, Baker DE et al. Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 2006; 28: 652-664.
21. Jeanfavre DD, Woska JR, Pargelis CA et al. Effect of deoxycoformycin and ValboroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase. Biochem Pharmacol 1996; 52: 1757-1765.
22. Korom S, Meester I, Maas E et al. CD26 expression and enzymatic activity in recipients of kidney allografts. Transplant Proc 2002; 34: 1753-1754.
23. Kubota T, Flentke GR, Bachovchin WW et al. Involement of dipeptidyl peptidase IV in an in vivo immune response. Clin Exp Immunol 1992; 89: 192-197.
24. Lindsay JR, Duffyt NA, McKillop AM et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 2005; 22: 654-657.
25. Mannucci E, Pala L, Ciani S et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 1168-1172.
26. Mentlein R. Dipetidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
27. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005; 48: 616-620.
28. Moore B, Edie ES, Abram JH. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J 1906; 1: 28-38.
29. Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagons-like peptide-1. Diabetologia 2005; 48: 608-611.
30. O'Harte FP, Abdel-Wahab YH, Conlon JM et al. Glycation of glucagon-like peptide-1(7-36) amide: characterization and impaired action on rat insulin secreting cells. Diabetologia 1998; 41: 1187-1193.
31. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of the glucagon-like peptide 1 in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3717-3723.
32. Tsu H, Chen X, Chen CT et al. 2-3-2-(2S)-2-Cyano-1-pyrrolidinyl-2- oxoethylamino-3-methyl-1-oxob utyl-1,2,3,4-tetrahydroisoquinoline: A potent, Sellective and Orally Bioavailable Dipeptide-Derived Inhibitor of Dipeptidyl Peptidase IV. J Med Chem 2006; 49: 373-380.
33. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969; 124: 261-266.
34. Uwaifo GI, Ratner RE. Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin N Am 2005; 34: 155-197.
35. Weber AE. Dipeptidyl Peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004; 47: 4135-4141.
36. Yamazaki K, Inoue T, Yasuda N et al. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alfa-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice. J Pharmacol Sci 2007; 104: 29-38.
37. Yasuda N, Inoue T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophy Res Commun 2002; 298: 779-784.
38. Zander M, Taskiran M et al. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001; 24: 720-725.
39. Zander M, Madsbad S, Deacon CF et al. The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. Diabetologia 2005; 49: 369-374.